Integrating EudraVigilance Data Into Signal Management: How to Choose the Right Approach

    Under Regulation (EU) 2025/1466, marketing authorisation holders (MAHs) are expected to monitor the data available in EudraVigilance as part of their signal management process. Yet the regulation and the European Medicines Agency’s (EMA) accompanying Questions and Answers document provide guidance without prescribing a single operating model.

    This leaves each company with a practical decision: where should EudraVigilance data enter the process, how frequently should it be reviewed, and should the same approach apply to every product?

    The right answer depends on the organisation. Choosing it requires a clear view of the available options, their trade-offs and the rationale behind the decision.

    In This Blog Post

    • What EMA clarifies and what remains for MAHs to decide
    • Three approaches to incorporating EudraVigilance data
    • How the eRMR supports signal detection
    • Which portfolio, risk and resource factors should drive the choice
    • How to document and maintain an inspection-ready approach

    What EMA Clarifies and What Remains Open

    EMA asks MAHs to explain in their signal management and pharmacovigilance procedures how EudraVigilance data are monitored and used alongside other sources. Monitoring frequency should be proportionate to the risk, known safety profile and characteristics of each product.

    Companies determine at which stage of the process the data are used. They may screen EudraVigilance as a primary source for signal detection, while EMA expects relevant EudraVigilance data to be considered during signal validation and evaluation.

    What is not prescribed is a universal model for staffing, screening intensity or product differentiation. MAHs must choose and justify an approach that is appropriate for their portfolio and sustainable with their available resources.

    Three Approaches to Integrating EudraVigilance Into Signal Management

    Viewed through the point at which EudraVigilance enters the process, three approaches can be considered. These are practical operating-model options, not three EMA-endorsed compliance models.

    1. Use EudraVigilance During Signal Validation and Evaluation

    Under this approach, a signal first detected through another source is assessed in the context of cases reported across the European Economic Area (EEA). EudraVigilance becomes an additional source of evidence during validation and evaluation, rather than a routinely screened primary detection source.

    Potential advantage: the workload remains relatively contained and can often fit within existing signal management routines. The principal needs are access to the data and personnel trained to interpret them.

    Trade-off: a potential signal that first emerges in EudraVigilance may reach the company later, when it is detected through the sources the MAH already monitors.

    The company should document how this approach meets its applicable monitoring obligations and why it is proportionate to its products.

    2. Screen EudraVigilance Systematically for Signal Detection

    A second approach adds EudraVigilance as a routine detection source. The database is screened at a defined frequency, alongside the company’s other sources of safety information.

    EMA’s electronic reaction monitoring report (eRMR) provides aggregated data and a disproportionality measure. This can broaden the view beyond the MAH’s own cases, particularly when internal safety data are limited.

    However, a statistical signal is not a validated safety signal. EMA’s EudraVigilance user manual describes the eRMR as a tool to support detection, not as a substitute for the more extensive review required during validation and evaluation.

    Potential advantage: systematic screening may identify emerging patterns that are not yet visible in the company’s own data.

    Trade-off: every screening cycle creates work. Outputs must be reviewed by qualified personnel, potential signals assessed, and decisions recorded. The approach therefore requires planning, capacity and consistent documentation.

    3. Apply a Risk-Based Approach Across the Portfolio

    The third option differentiates between products. EudraVigilance is used as a detection source where the product’s risk profile justifies it, while other products rely on its use from validation and evaluation onward, within the MAH’s documented overall monitoring approach.

    Potential advantage: effort can be directed towards products where additional screening is most valuable, rather than applying identical intensity across the portfolio.

    Trade-off: the organisation needs clear criteria for assigning products to different approaches. Those criteria must be documented, reviewed and updated as safety profiles, exposure or portfolio composition change.

    This is not necessarily the simplest model to implement. It may require an initial risk-tiering exercise and ongoing governance to keep the distinctions defensible.

    Which Criteria Should Drive the Decision?

    Different companies can reasonably reach different conclusions. The important point is to make the decision on the basis of the products and operating model involved, rather than assuming that the most extensive screening programme is always the most appropriate.

    Factors to consider include:

    • Product risk and maturity: known safety profile, exposure, emerging risks and the characteristics of individual products
    • Portfolio size and complexity: the number of products, substances and markets that need to be managed
    • Internal expertise: the ability to interpret statistical outputs, assess cases and distinguish potential signals from noise
    • Available resources: capacity to perform and document screening and subsequent review at the selected frequency
    • Operating model: whether work is performed in-house, outsourced or shared, and how responsibilities are allocated
    • Experience with EudraVigilance: familiarity with the database, eRMR and relevant assessment procedures

    A smaller company with a few well-characterised products and a business managing a growing portfolio of newer substances may adopt different approaches and both be able to justify them. Even within one company, different parts of the portfolio may warrant different levels of monitoring.

    Documenting an Approach That Can Withstand Inspection

    The decision is only useful if it is translated into clear procedures and routine practice. EMA expects MAHs to describe their approach in signal management and pharmacovigilance documentation.

    At a minimum, the documentation should make it possible to explain:

    • Which approach applies to each product or product group, and why
    • At which signal management stages EudraVigilance data are considered
    • How frequently monitoring takes place and how that frequency was determined
    • Who performs screening, validation, evaluation and oversight
    • How outputs, assessments and decisions are recorded
    • What triggers reassessment when products, resources or guidance change

    A documented rationale is more valuable than an ambitious process that cannot be sustained. It gives the organisation a basis for explaining its choices during an audit or inspection and for revisiting them as circumstances evolve.

    EMA has indicated that GVP Module IX will be updated. Procedures should therefore be sufficiently controlled and adaptable to accommodate further guidance when applicable.

    Think Beyond the Pharmacovigilance Workload

    Signal management does not operate in isolation. Validated signals can lead to regulatory actions, including product information variations and consideration in periodic safety update reports (PSURs), where applicable.

    How EudraVigilance data enter the process can therefore affect more than pharmacovigilance capacity. It can influence product information maintenance, cross-functional responsibilities and regulatory timelines throughout the product lifecycle.

    The goal is not to select the approach that looks most comprehensive on paper. It is to establish one that the company can explain, sustain and adapt as its portfolio evolves.

    Choose a Proportionate, Sustainable Signal Management Model

    Regulation (EU) 2025/1466 makes EudraVigilance monitoring a practical operating-model decision for MAHs. Whether an organisation uses the database primarily during validation and evaluation, screens it systematically for detection, or differentiates its approach by product, the choice needs to be risk-based and documented.

    QbD Group supports pharmaceutical and biotech companies with pharmacovigilance processes, signal management, procedural development and inspection readiness.

    Unsure how to integrate EudraVigilance into your existing signal management process? Get in touch with our Pharmacovigilance experts to define an approach that fits your portfolio, resources and regulatory responsibilities.

    Sources